Abstract:Tyrosine threonine kinase (TTK) is the key component of the spindle assembly checkpoint (SAC) that ensures correct attachment of chromosomes to the mitotic spindle and thereby their precise segregation into daughter cells by phosphorylating specific substrate proteins. The overexpression of TTK has been associated with various human malignancies, including breast, colorectal and thyroid carcinomas. TTK has been validated as a target for drug development, and several TTK inhibitors have been discovered. In this study, ligand and structure-based alignment as well as various partial charge models were used to perform 3D-QSAR modelling on 1H-Pyrrolo[3,2-c] pyridine core containing reported inhibitors of TTK protein using the comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) approaches to design better active compounds. Different statistical methods i.e., correlation coefficient of non-cross validation (r2), correlation coefficient of leave-one-out cross-validation (q2), Fisher's test (F) and bootstrapping were used to validate the developed models. Out of several charge models and alignment-based approaches, Merck Molecular Force Field (MMFF94) charges using structure-based alignment yielded highly predictive CoMFA (q2 = 0.583, Predr2 = 0.751) and CoMSIA (q2 = 0.690, Predr2 = 0.767) models. The models exhibited that electrostatic, steric, HBA, HBD, and hydrophobic fields play a key role in structure activity relationship of these compounds. Using the contour maps information of the best predictive model, new compounds were designed and docked at the TTK active site to predict their plausible binding modes. The structural stability of the TTK complexes with new compounds was confirmed using MD simulations. The simulation studies revealed that all compounds formed stable complexes. Similarly, MM/PBSA method based free energy calculations showed that these compounds bind with reasonably good affinity to the TTK protein. Overall molecular modelling results suggest that newly designed compounds can act as lead compounds for the optimization of TTK inhibitors.

Common Pharmacophore Model and 3D-QSAR Analysis of Two Different Tyrphostin Families

Pharmacophore Model Analysis Of Novel Tyrphostins

Combined Structure-Based Pharmacophore And 3d-Qsar Studies On Phenylalanine Series Compounds As Tph1 Inhibitors

Pharmacophore Model and 3D-QSAR Study of Two Kinds of HCVNS3 Serine Protease Inhibitors

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors

Pharmacophore Modeling Study Based on Known Spleen Tyrosine Kinase Inhibitors Together with Virtual Screening for Identifying Novel Inhibitors.

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

Pharmacophore Modeling Studies of Type I and Type II Kinase Inhibitors of Tie2.

Refinement and 3D‐QSAR Studies of Inhibitors of Cyclophilin A Containing Amide Linker

Development of Novel Selective Pharmacophore for Tankyrase Inhibitors

ChemInform Abstract: 3D QSAR Analyses of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment.

3D-QSAR, molecular docking, and new compound design of pyrimidine derivatives as Src small molecule inhibitors

3D-QSAR and 3D-QSSR Studies of Thieno[2,3-D]pyrimidin-4-yl Hydrazone Analogues As CDK4 Inhibitors by CoMFA Analysis

A pharmacophore model specific to active site of CYP1A2 with a novel molecular modeling explorer and CoMFA.

Combined 3D-QSAR, molecular docking and dynamics simulations studies to model and design TTK inhibitors

2D QSAR and Atom based 3D QSAR study of Tropomyosin Receptor Kinases inhibition by pyrazol derivatives

Three-Dimensional Quantitative Structure-Activity Relationship of 4,5,6,7-Tetrahydrothienopyridines Analogues As Glucose-6-Phosphatase Inhibitors

3D-QSAR and Docking Study on 3-Benzimidazol-2-ylhydroquinolin-2-one Derivatives As VEGFR-2 Tyrosine Kinase Inhibitors

Towards More Accurate Pharmacophore Modeling: Multicomplex-based Comprehensive Pharmacophore Map and Most-Frequent-feature Pharmacophore Model of CDK2.

3D-QSAR Modeling and Molecular Docking Study on Mer Kinase Inhibitors of Pyridine-Substituted Pyrimidines